Tetra Pak Bioreactor RF enables stable, scalable fermentation with reduced risk, faster start-up and up to 12 per cent lower operational costs1, from pilot to full production Tetra Pak announces the…

Tetra Pak Bioreactor RF enables stable, scalable fermentation with reduced risk, faster start-up and up to 12 per cent lower operational costs1, from pilot to full production

Tetra Pak announces the launch of the Tetra Pak Bioreactor RF, its first industrial bioreactor. The launch follows Tetra Pak’s acquisition of Bioreactors.net in December 2025 and marks a significant step in expanding the company’s offering for industrial fermentation and New Food production.

New Food fermentation, where microorganisms such as yeast, bacteria and fungi convert raw materials into valuable food ingredients, is becoming an increasingly important capability for food and ingredient producers. As the industry looks to diversify ingredient sourcing and improve resource efficiency, producers are moving rapidly from pilot testing to industrial-scale production. These companies are therefore seeking systems that deliver consistent performance while reducing variability and operational burden.

Tetra Pak Bioreactor RF is a fermentation vessel designed to maintain stable conditions while providing operators with actionable process insight. From pilot validation and first industrial runs through to full-scale production, the system delivers repeatable performance without increasing operational complexity.

“Industrial fermentation succeeds when performance is repeatable, day after day,” says Rafael Barros, Director of the New Food Business Stream at Tetra Pak. “Tetra Pak Bioreactor RF is designed to reduce operational risk and remove complexity, helping operators stay in control.”

Tetra Pak Bioreactor RF is pre-assembled and factory-tested, enabling faster installation and commissioning, while reducing disruption to production planning. Its integrated platform design removes the need for separate support structures, lowering installation costs and complexity. These features can help reduce investment costs by up to 8 per cent compared with conventional industrial bioreactors.